SMARCA4 (BRG1) and SMARCB1 (INI1) expression in TTF-1 negative neuroendocrine carcinomas including merkel cell...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Loss of function in SMARCA4 and SMARCB1 is linked to various cancers.
• The role of these tumor suppressors in high-grade neuroendocrine carcinoma is not well understood.
• TTF-1 negative neuroendocrine carcinomas require further investigation for potential therapeutic strategies.

Purpose of the Study:

• To investigate BRG1 (SMARCA4) and INI1 (SMARCB1) expression loss in TTF-1 negative neuroendocrine carcinomas.
• To determine if these tumors are analogous to small-cell carcinoma of the ovary, hypercalcemic type.
• To explore the potential role of these tumor suppressor genes in high-grade neuroendocrine carcinoma.

Main Methods:

• Immunohistochemical analysis of BRG1 and INI1 expression in Small cell carcinoma (SmCC), Large cell neuroendocrine carcinoma (LCNEC), and Merkel cell carcinoma (MCC).
• Cases were categorized based on TTF-1 status (positive or negative).
• Expression patterns were classified as intact, hybrid, or complete loss of nuclear staining.

Main Results:

• SMARCA4 (BRG1) loss was observed in one TTF-1 negative SmCC (lung).
• In TTF-1 negative LCNEC, one lung case showed complete SMARCA4 (BRG1) loss and partial SMARCB1 (INI1) loss; one lymph node case had hybrid SMARCA4 (BRG1) expression with intact SMARCB1 (INI1).
• All TTF-1 positive cases and all MCC cases exhibited intact BRG1 and INI1 expression.

Conclusions:

• SMARCA4 (BRG1) deficiency is present in a subset of neuroendocrine carcinomas (NEC), particularly TTF-1 negative pulmonary LCNEC.
• Inactivation of SMARCA4 in these tumors warrants further study for targeted therapy, such as EZH2 inhibitors.
• BRG1 and INI1 expression remain intact in MCC, suggesting distinct biological pathways.